Regeneron joins Lilly in validating the Covid antibody approach
Like Lilly Regeneron reports promising but not emphatic data with its antibody treatment, and the question turns to approvability.
EASL 2020 – Assembly finds a partner as hepatitis B inches forward
As fresh data confirm the promise of RNAi technology in hepatitis B, Assembly brings on Arbutus for its combo strategy.
Curevac rides the Covid wave
Curevac’s market cap has ballooned almost fivefold since floating, sending the mRNA company into the record books.
Covid-19 vaccines remain hot – in spite of Inovio
Biontech and Pfizer come roaring back with the first human data on BNT162, a day after Inovio’s effort disappointed.
